Number of pages: 100 | Report Format: PDF | Published date: May 01, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023 to 2031
Report Attribute |
Details |
Market Size Value in 2022 |
US$ 209.7 million |
Revenue Forecast in 2031 |
US$ 482.46 million |
CAGR |
9.70% |
Base Year for Estimation |
2022 |
Forecast Period |
2023 to 2031 |
Historical Year |
2021 |
Segments Covered |
Treatment type, Application, End user, and Region |
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global intratumoral cancer market was valued at US$ 209.7 million in 2022 and is expected to register a revenue CAGR of 9.70% to reach US$ 482.46 million by 2031.
Intratumoral Cancer Market Fundamentals
Intratumoral cancer therapies are treatments that are directly delivered into the tumor, rather than being administered through traditional systemic routes like intravenous infusion. These therapies can be delivered via injections, infusions, or local implantation devices. Intratumoral therapies can include a range of treatments, such as chemotherapy, radiation therapy, immunotherapy, and gene therapy. The goal of these therapies is to destroy cancer cells within the tumor and minimize damage to the healthy tissues. One advantage of intratumoral therapies is that they can be targeted to specific areas, which can reduce the risk of side effects associated with traditional systemic therapies. Additionally, some cancer types may be more responsive to intratumoral therapies, therefore showing better treatment outcomes. However, there are also some limitations to intratumoral therapies. For example, these therapies may not be effective for tumors that have spread throughout the body. Additionally, the delivery of intratumoral therapies can be challenging, and the treatment may not reach all areas of the tumor.
[10]
Intratumoral Cancer Market Dynamics
There are several drivers and trends in the intratumoral cancer therapies market. The globally rising incidence of cancer is a major driver of the intratumoral cancer therapies market growth. Additionally, advances in imaging and drug delivery technologies have enabled the development of more effective intratumoral cancer therapies. For instance, the use of nanoparticles and liposomes for drug delivery has shown promise in improving the efficacy of intratumoral therapies. In addition, immunotherapy has emerged as a promising approach for cancer treatment, therefore the use of intratumoral immunotherapy is on the rise. Intratumoral immunotherapy involves injecting immunomodulatory agents directly into the tumor. With the increasing focus on personalized medicine, intratumoral therapies are being developed to target specific molecular characteristics of individual tumors. This approach can improve the efficacy of the treatment while minimizing side effects. Major pharmaceutical companies are investing heavily in the development of intratumoral cancer therapies, which is driving the market growth. Additionally, governments and non-profit organizations are providing funding for research in this area, which is further accelerating the development of new therapies.
Although the use of intratumoral therapies has shown promise in preclinical studies, there is a limited clinical data to support their efficacy in humans. This lack of data may limit adoption and investment in the market. Delivering intratumoral therapies can be challenging, as the tumors may be difficult to access, or the therapies may not reach certain areas, limiting the treatment effectiveness.
Intratumoral therapies have potential adverse events, such as inflammation and pain at the injection site, as well as systemic side effects. These adverse events may limit the use of intratumoral therapies, particularly in patients who are already experiencing significant side effects from other treatments. Intratumoral therapies can be expensive, as they often require specialized delivery methods and equipment. This may limit the accessibility to treatments, particularly in lower-income countries. Intratumoral therapies may not be suitable for all types of tumors or for tumors that have spread to other parts of the body. This can limit the market potential of intratumoral therapies.
Intratumoral Cancer Market Ecosystem
The global intratumoral cancer market has been analyzed from the following perspectives: treatment type, application, end user, and region.
Intratumoral Cancer Market by Treatment Type
[23]
Based on the treatment types, the global intratumoral cancer market can be further segmented into monoclonal antibodies, vaccines, cell therapies, immune system modulators, checkpoint inhibitors, and others.
The monoclonal antibodies (mAbs) segment dominates the global intratumoral cancer market. Monoclonal antibodies have shown high efficacy in treating various types of cancers, including solid tumors. They work by targeting specific proteins on the surface of cancer cells, thereby blocking their growth. Monoclonal antibodies are highly specific to their target proteins, which means they can selectively target cancer cells without harming healthy cells. This specificity reduces the risk of side effects and improves patient outcomes. Monoclonal antibodies can be used in combination with other cancer treatments, such as chemotherapy and radiation therapy, to enhance their effectiveness. They can also be engineered to carry drugs or radioactive isotopes directly to cancer cells, further improving their therapeutic potential. Monoclonal antibodies are widely available in the market and are used extensively in clinical practice. This has resulted in a well-established infrastructure for the development, production, and distribution of mAbs, making them a popular choice for intratumoral cancer therapy. The incidence of cancer is increasing globally, and there is a growing demand for effective cancer therapies. Monoclonal antibodies have emerged as a promising class of drugs for cancer treatment, driving their demand in the global intratumoral cancer therapies market.
Similarly, the immune system modulators segment accounts for a notable revenue share of the global intratumoral cancer market. Immune system modulators work by enhancing the body's natural immune response to cancer cells, thereby enabling it to fight the disease more effectively. This mechanism of action has shown high efficacy in treating various cancer types. Immune system modulators are targeted therapies, which means they can selectively target cancer cells without harming healthy cells. This reduces the risk of side effects and improves patient outcomes. Immune system modulators can be used in combination with other cancer treatments, such as chemotherapy and radiation therapy, to enhance their effectiveness. This has led to the development of new combination therapies that have shown superior results compared to single-agent therapies. Immune system modulators are a relatively new class of drugs, and ongoing research is uncovering new targets and mechanisms of action that can further improve their therapeutic potential. This has led to a growing pipeline of immune system modulators in clinical development, driving their demand in the global intratumoral cancer market. The incidence of cancer is increasing globally, and there is a growing demand for effective cancer therapies. Immune system modulators have emerged as a promising class of drugs for cancer treatment, driving their demand in the global intratumoral cancer market.
Intratumoral Cancer Market by Application
Based on the applications, the global intratumoral cancer market is segmented into lung cancer, melanoma, prostate cancer, breast cancer, and others.
The lung cancer segment accounts for the largest revenue share in the global intratumoral cancer market. Lung cancer is one of the most common types of cancer worldwide, with a high incidence and mortality rate. This has led to a greater demand for effective lung cancer treatments, including intratumoral cancer therapies. Lung cancer has historically been difficult to treat, and traditional treatments like chemotherapy and radiation therapy have limited effectiveness. Intratumoral cancer therapies offer a new treatment option for lung cancer patients, with the potential for better outcomes. This has led to increased interest and demand for intratumoral therapies in lung cancer market. Targeted therapies can selectively aim at cancer cells in the lungs without harming healthy cells. This reduces the risk of side effects and improves patient outcomes. There is ongoing research into new intratumoral cancer therapies for lung cancer, which is driving innovation and growth in the market. This includes the development of new drugs, combination therapies, and treatment protocols that offer the potential for even enhanced outcomes for lung cancer patients.
Intratumoral Cancer Market by End User
Based on end user, the global intratumoral cancer market is segmented into hospitals, cancer research centers, and others.
Hospitals dominate the global intratumoral cancer market. Hospitals have well-established infrastructure and facilities for cancer diagnosis, treatment, and care, making them the preferred choice for cancer patients. Hospitals have dedicated oncology departments with trained healthcare professionals, specialized equipment, and support staff, which enables them to provide comprehensive care to cancer patients. Hospitals have access to the latest technologies and medical devices for cancer treatment, including intratumoral cancer therapies. They have the expertise and resources to deliver these therapies safely and effectively, which increases patient confidence and trust in the offered services. Hospitals play a critical role in research and development for intratumoral cancer therapies. They conduct clinical trials, develop new treatment protocols, and collaborate with pharmaceutical companies and academic institutions to advance the field of cancer therapy. Hospitals typically have a high volume of cancer patients, which means they have greater experience in treating a variety of cancer types and stages. This expertise enables them to deliver better outcomes for patients and attract more referrals from other healthcare providers. Hospitals have a better chance of receiving reimbursement for intratumoral cancer therapies from insurance providers and government programs. This gives easier treatment access to patients and reduces the financial burden of treatment.
Intratumoral Cancer Market by Region
Based on the region, the global intratumoral cancer market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
North America dominates the global intratumoral cancer market and is expected to retain its dominance during the projected timeframe from 2023 to 2031. North America has a highly developed healthcare infrastructure, with advanced medical technologies and facilities for cancer diagnosis and treatment. This enables healthcare providers to deliver intratumoral cancer therapies more effectively, leading to better patient outcomes. The incidence of cancer is increasing globally, and North America is no exception. Therefore, there is a greater demand for effective cancer therapies in the region, including intratumoral cancer therapies. Healthcare providers in North America benefit from favorable reimbursement policies for cancer treatments. This makes it easier for patients to access these therapies and reduces the financial burden of treatment. North America has a robust research and development ecosystem, with leading pharmaceutical companies, academic institutions, and research organizations working to advance the field of cancer therapy. This has led to the development of new therapies and treatment protocols, driving intratumoral cancer market demand. North America has a strong regulatory environment for healthcare products, including cancer treatments. This ensures that these therapies are safe and effective, and it gives healthcare providers and patients confidence in the quality of care they receive.
Competitive Landscape
The prominent players operating in the global intratumoral cancer market are:
Intratumoral cancer therapies are treatments that are directly delivered into the tumor, rather than being administered through traditional systemic routes like intravenous infusion.
The oncology segment dominates the global intratumoral cancer market with the largest revenue share.
The global intratumoral cancer market will grow at a revenue CAGR of 9.70% during the projected period.
Asia Pacific is projected to be the fastest-growing region in the intratumoral cancer market.
GlaxoSmithKline Plc., Pfizer Inc., Novartis AG, and Merck & Co. Inc. are some of the key market players.
The estimated market size of the intratumoral cancer market is US$ 482.46 million in 2031.
*Insights on financial performance are subject to the availability of information in the public domain